Listed by the USPTO as FETTEROLF, BRANDON J
Tech Center 1600 • Art Units: 1622 1626 1628 1629 1642
This examiner grants 51% of resolved cases
Fetterolf, Brandon J, works in Tech Center 1600 and Art Unit 1622. The record includes 232 resolved cases, with an allowance rate of 50.9% and a median of 1290 days to allowance. The interview lift is 20.1%, suggesting that interviews may provide useful but limited support during a lengthy prosecution process.
The listed companies are Astrazeneca AB, Novartis AG, and Monash University. The leading firms are Abel Schillinger, LLP, Apex Attorneys at Law, LLP, and Arnall Golden Gregory LLP. Practitioners should combine clear written responses with selective interview use and realistic timing expectations.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18729949 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | Non-Final OA | Novartis AG |
| 18033724 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | Non-Final OA | MERCK PATENT GMBH |
| 18737447 | SUBSTITUTED BENZOFURAN PROPYL AMINE MODULATORS OF MONOAMINERGIC TRANSPORTERS | Non-Final OA | EmpathBio, Inc. |
| 18857347 | FGFR2 INHIBITOR COMPOUNDS | Non-Final OA | ELI LILLY AND COMPANY |
| 17912272 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | Final Rejection | THE GENERAL HOSPITAL CORPORATION |
| 17783455 | METHODS OF CONTROLLING OR PREVENTING INFESTATION OF PLANTS BY A PHYTOPATHOGENIC MICROORGANISM OF THE GENUS MACROPHOMINA SPP. | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18030390 | NOVEL REDOX-BASED THERAPEUTIC APPROACH FOR TREATMENT OF CANCER | Final Rejection | THE PENN STATE RESEARCH FOUNDATION |
| 17906138 | TREATMENT OF EPILEPSY | Final Rejection | Katholieke Universiteit Leuven |
| 18853504 | COMBINATION THERAPY FOR TREATING CANCER | Non-Final OA | AstraZeneca AB |
| 18849729 | INJECTABLE PREPARATION COMPRISING ISOXAZOLINE DERIVATIVE, AND PREPARATION METHOD THEREFOR | Non-Final OA | LG CHEM, LTD. |
| 18860376 | TREATMENT OF NEUROLOGICAL DISORDERS | Non-Final OA | Praxis Precision Medicines, Inc. |
| 17916904 | TOPICAL USE OF ERLOTINIB FOR TREATING KERATODERMAS IN CHILDREN | Final Rejection | UNIVERSITE PARIS-SACLAY |
| 18014545 | THERAPY OF POST-OPERATIVE NAUSEA AND VOMITING | Final Rejection | LXO US, Inc. |
| 17922890 | DOSING METHODS FOR TREATMENT OF CARDIOVASCULAR CONDITIONS | Non-Final OA | IMBRIA PHARMACEUTICALS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy50.9% of resolved applications examined by Brandon J Fetterolf were allowed (232 resolved cases), compared with 60.5% across Art Unit 1622 over the last five years.
This examiner's interview lift is +20.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Brandon J Fetterolf took 1,290 days on average from filing to allowance.
Brandon J Fetterolf examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).